BR112018067967A2 - tratamento de pacientes com hipercolesterolemia familiar homozigótica por meio de terapia hipolipemiante - Google Patents

tratamento de pacientes com hipercolesterolemia familiar homozigótica por meio de terapia hipolipemiante

Info

Publication number
BR112018067967A2
BR112018067967A2 BR112018067967A BR112018067967A BR112018067967A2 BR 112018067967 A2 BR112018067967 A2 BR 112018067967A2 BR 112018067967 A BR112018067967 A BR 112018067967A BR 112018067967 A BR112018067967 A BR 112018067967A BR 112018067967 A2 BR112018067967 A2 BR 112018067967A2
Authority
BR
Brazil
Prior art keywords
treatment
patients
homozygous familial
familial hypercholesterolaemia
hypolipidemic therapy
Prior art date
Application number
BR112018067967A
Other languages
English (en)
Inventor
L Bisgaier Charles
Original Assignee
Gemphire Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gemphire Therapeutics Inc filed Critical Gemphire Therapeutics Inc
Publication of BR112018067967A2 publication Critical patent/BR112018067967A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Abstract

métodos para o tratamento de hipercolesterolemia familiar homozigótica através da administração de gemcabene como adjuvante de outra terapia hipolipemiante e/ou dieta modificada.
BR112018067967A 2016-02-26 2017-02-27 tratamento de pacientes com hipercolesterolemia familiar homozigótica por meio de terapia hipolipemiante BR112018067967A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662300393P 2016-02-26 2016-02-26
PCT/US2017/019750 WO2017147598A1 (en) 2016-02-26 2017-02-27 Treatment of patients with homozygous familial hypercholesterolemia on lipid lowering therapy

Publications (1)

Publication Number Publication Date
BR112018067967A2 true BR112018067967A2 (pt) 2019-01-15

Family

ID=59685647

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112018067967A BR112018067967A2 (pt) 2016-02-26 2017-02-27 tratamento de pacientes com hipercolesterolemia familiar homozigótica por meio de terapia hipolipemiante

Country Status (14)

Country Link
EP (1) EP3419614A4 (pt)
JP (1) JP2019506423A (pt)
KR (1) KR20180115722A (pt)
CN (1) CN108697677A (pt)
AU (1) AU2017224230A1 (pt)
BR (1) BR112018067967A2 (pt)
CA (1) CA3014919A1 (pt)
HK (1) HK1257556A1 (pt)
IL (1) IL261117A (pt)
MX (1) MX2018010096A (pt)
PH (1) PH12018501790A1 (pt)
RU (1) RU2018133690A (pt)
SG (2) SG11201806894PA (pt)
WO (1) WO2017147598A1 (pt)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20210093900A (ko) * 2018-10-18 2021-07-28 젬파이어 세러퓨틱스 인코포레이티드 젬카빈, 이의 약학적으로 허용가능한 염, 이의 조성물 및 이의 사용 방법
WO2020113041A1 (en) * 2018-11-30 2020-06-04 Hdl Therapeutics, Inc Methods for treating lipid-related diseases including xanthomas, carotid artery stenoses, and cerebral atherosclerosis
CN112138008B (zh) * 2020-09-30 2022-06-17 郑州大学 洛美他派在制备抗肿瘤药物中的应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030105154A1 (en) * 2001-10-24 2003-06-05 Bisgaier Charles Larry Statin-carboxyalkylether combinations
CN101534641A (zh) * 2006-03-22 2009-09-16 哈佛大学校长及研究员协会 治疗高胆固醇血症和动脉粥样硬化的方法和组合物
AU2013207423B2 (en) * 2012-01-06 2017-10-12 Gemphire Therapeutics Inc. Methods of reducing risk of cardiovascular disease

Also Published As

Publication number Publication date
HK1257556A1 (zh) 2019-10-25
JP2019506423A (ja) 2019-03-07
EP3419614A4 (en) 2019-10-09
KR20180115722A (ko) 2018-10-23
CA3014919A1 (en) 2017-08-31
RU2018133690A3 (pt) 2020-05-29
WO2017147598A1 (en) 2017-08-31
IL261117A (en) 2018-10-31
RU2018133690A (ru) 2020-03-26
PH12018501790A1 (en) 2019-06-17
MX2018010096A (es) 2018-11-09
SG11201806894PA (en) 2018-09-27
SG10201912756XA (en) 2020-02-27
AU2017224230A1 (en) 2018-08-30
CN108697677A (zh) 2018-10-23
EP3419614A1 (en) 2019-01-02

Similar Documents

Publication Publication Date Title
CY1123459T1 (el) Χρηση των κανναβινοειδων στη θεραπεια του συμπλεγματος οζωδους σκληρυνσης
BR112015019995A2 (pt) Combinação terapêutica envolvendo anticorpos contra claudina 18.2 para tratamento de câncer
MX2020009780A (es) Compuestos de inhibidor de autotaxina.
BR112017006664A2 (pt) terapias de combinação
BR112017011923A2 (pt) bactéria modificada para tratar doenças associadas com hiperamonemia
WO2016025635A3 (en) Combination therapy for treating cancer
BR112017007975A2 (pt) composições e métodos para o tratamento de disfunção das glândulas meibomianas
BR112015022597A2 (pt) partículas modificadoras da imunidade para o tratamento de inflamação
BR112016018408A2 (pt) moléculas de anticorpo à lag-3 e usos das mesmas
EA201790195A1 (ru) Способы лечения рака с применением ингибиторов tigit и противораковых агентов
EA201591340A1 (ru) Модулятор андрогенного рецептора и его применения
BR112015027282A8 (pt) formulação líquida e kit compreendendo fenfluramina, e usos da mesma no tratamento de síndrome de dravet
BR112015023203A2 (pt) métodos para tratamento de câncer, para aumentar a eficiência de um tratamento de câncer, para retardar e/ou prevenir o desenvolvimento de câncer, para tratar um indivíduo com câncer, para aumentar a sensibilidade para um agente de terapia para câncer, para estender um período de sensibilidade e para estender a duração da resposta para uma terapia para câncer, e usos
BR112017000301A2 (pt) tratamento de leucemia com inibidores de histona desacetilase
MX2016014306A (es) Marcadores para terapia con lipoproteinas de alta densidad (hdl).
BR112017010761A2 (pt) tratamento de doenças associadas à ativação de célula estrelada hepática com o uso de terapias de redução de amônia
BR112015026297A2 (pt) terapia combinada composta por um inibidor tor quinase e um composto de 5-quinazolinona substituído para o tratamento de câncer
BR112017018964A2 (pt) uso de plinabulin e métodos para tratar tumor cerebral
CL2016001076A1 (es) (aza) piridopirazolopirimidinonas e indazolopirimidinonas como inhibidores de fibrinolosis.
WO2016043874A3 (en) Combination therapy for treating cancer
BR112018013063A2 (pt) combinação terapêutica inibidora de bromodomínio e proteína extra-terminal
NI201600070A (es) Inhibidores tetracíclicos de autotaxina
BR112019008384A2 (pt) composição farmacêutica, processos para tratamento e seus usos
BR112016027043A8 (pt) combinação, composição farmacêutica compreendendo glucocorticoide e edo-s101, kit e uso no tratamento de câncer
BR112017025533A2 (pt) método para tratar câncer em um paciente humano

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements